Nov 07, 2024
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Aug 08, 2024
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
Aug 06, 2024
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Jul 09, 2024
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Jun 24, 2024
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Jun 04, 2024
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
Apr 30, 2024
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Mar 12, 2024
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Jan 02, 2024
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Feb 10, 2021
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Jan 27, 2021
Regulus Announces Addition to Board of Directors
Jan 05, 2021
Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Nov 02, 2020
Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi
Oct 15, 2020
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sep 03, 2020
Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare Conference
Aug 31, 2020
Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements
Aug 13, 2020
Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates
Aug 06, 2020
Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Aug 03, 2020
Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer
Jul 29, 2020
Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)